Daniel de Boer
Chief Executive Officer bij PROQR THERAPEUTICS N.V.
Vermogen: 2 M $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Daniel de Boer
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 30 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Daniel de Boer via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BAXTER INTERNATIONAL INC. | Medical Specialties | Sales & Marketing | |
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Treasurer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal | |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| GALAPAGOS NV | Biotechnology | President | |
| Nyenrode Business Universiteit | College/University | Undergraduate Degree Director/Board Member | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Chief Operating Officer | |
| SPYRE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
The British United Provident Association Ltd.
 The British United Provident Association Ltd. Life/Health InsuranceFinance The British United Provident Association Ltd. provides healthcare products and services. It offers health, dental and travel insurance, optical and audiology, and care homes. The company was founded on April 3, 1947 and is headquartered in London, the United Kingdom. | Life/Health Insurance | Sales & Marketing | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Sterling Winthrop, Inc.
 Sterling Winthrop, Inc. Electronics/AppliancesConsumer Durables Part of GSK Plc, Sterling Winthrop, Inc. is a private company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million. | Electronics/Appliances | Corporate Officer/Principal | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| The University of Texas at Austin | College/University | Doctorate Degree Doctorate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin | |
| ABLYNX | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| University of Amsterdam | College/University | Graduate Degree Graduate Degree | |
| University of Leiden | College/University | Corporate Officer/Principal Graduate Degree | |
| University of Utrecht | College/University | Graduate Degree Undergraduate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Medical Specialties | Corporate Officer/Principal | |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Founder Private Equity Investor | |
| Ohmeda Pharmaceuticals | Corporate Officer/Principal | ||
| SENSORION | Pharmaceuticals: Major | Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
| VERASTEM, INC. | Biotechnology | Director/Board Member Director/Board Member Sales & Marketing | |
AgBiome INC
 AgBiome INC BiotechnologyHealth Technology AgBiome LLC provides early stage research and discovery to the agriculture industry. It develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. The firm applies genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and yield. The company was founded by Jeff Dangl, John N. Couch, Paul Schulze-Lefert, Scott J. Uknes, John Ryals, Eric R. Ward, and Mike Koziel in 2012 and is headquartered in Research Triangle Park, NC. | Biotechnology | Director/Board Member | |
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Miscellaneous Commercial Services | Founder Director/Board Member Chairman | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Cadena Bio, Inc.
 Cadena Bio, Inc. Pharmaceuticals: OtherHealth Technology Cadena Bio, Inc. engages in the manufacture of supplements for human health and nutrition by feeding the microbiome. The company was founded in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Other | President | |
Sanofi-Aventis, Inc.
 Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis, Inc. is a private company that manufactures and wholesales pharmaceutical products. The company is based in Scottsdale, AZ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Alnylam Germany GmbH
 Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The private company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | Biotechnology | Chief Executive Officer | |
Alnylam UK Ltd.
 Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The private company is based in Maidenhead, UK. | Biotechnology | Director/Board Member | |
| Janssen Biotherapeutics | Corporate Officer/Principal Corporate Officer/Principal | ||
| X4 PHARMACEUTICALS, INC. | Biotechnology | Founder Director/Board Member | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Director/Board Member | |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| BIOSURGERY S.R.L. | Corporate Officer/Principal | ||
| DIANTHUS THERAPEUTICS, INC. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 26 |
| Nederland | 9 |
| Verenigd Koninkrijk | 6 |
| België | 4 |
| Duitsland | 4 |
Sectoraal
| Health Technology | 34 |
| Consumer Services | 9 |
| Finance | 3 |
| Commercial Services | 3 |
| Consumer Durables | 2 |
Operationeel
| Director/Board Member | 131 |
| Corporate Officer/Principal | 52 |
| Independent Dir/Board Member | 32 |
| Chief Tech/Sci/R&D Officer | 23 |
| Chairman | 20 |
Sterkste connecties
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Henri A. Termeer | 42 |
| Alison Lawton | 24 |
| James Shannon | 22 |
| Theresa Heggie | 16 |
| Domenico Valerio | 15 |
| René Beukema | 12 |
| Naveed Shams | 11 |
| David Rodman | 10 |
| Noreen Henig | 10 |
| Robert Friesen | 9 |
| Aniz Girach | 7 |
| Bart Filius | 7 |
| Smital Shah | 7 |
| Paul Baart | 7 |
- Beurs
- Insiders
- Daniel de Boer
- Bedrijfsconnecties
